About Us

Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of tumour-associated macrophages (TAMs). We are currently engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility across a broad spectrum of cancers. We are also more broadly interested in the potential to target GPR65 for benefit in a range of other serious diseases.

Pathios employs a cutting-edge scientific approach to mapping the signalling of key GPCRs on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach Pathios has identfied GPR65 as a key innate immune checkpoint on TAMs and now aims to rapidly deliver on the promise of novel therapeutic agents targeting this receptor. We combine a team of experienced scientific leaders with a number of strategic external partnerships to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.

Tumour Associated Macrophages (TAMs) Key Facts


TAMs are by far the most abundant infiltrating immune cells in tumours, making up to 50% of cells


A high density of immunosuppressive TAMs in the tumour microenvironment is linked to poor survival


No approved therapies currently target TAMs in cancer

“Pathios is founded on the simple principle that malignant tumours are characterized by an abnormally low pH that signals to tumour-associated macrophages (TAMs) to fundamentally change their characteristics in a detrimental way for the patient. At the apex of this signalling is the cell-surface receptor, GPR65, which senses the acidic tumour microenvironment and renders TAMs as highly immunosuppressive. Pathios’ Macrophage Conditioning approach is focused on finding drugs that block GPR65 to prevent this signaling and unlock the enormous power of the innate immune system in the fight against cancer” Dr. Stuart Hughes, Chief Executive Officer, Pathios Therapeutics